Immunovant, Inc. (IMVT)

Immunovant, Inc. (IMVT) is a healthcare company (biotechnology) based in the United States. The share price is $33.04, down 0.72% on the day, which values the company at $6.84B. Price as of 17 Nov 2026, 17:14 UTC, from Yahoo Finance.

Key facts

Share price
$33.04−0.72% today
Market value
$6.84B
200-week average
$26.2126% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Immunovant, Inc. in more detail

IMVT trades at -11.7× next year's expected earnings. It sits 26% above its 200-week average of $26.21.

In its favour: More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

3 of the superinvestors tracked here hold IMVT, including Andrew Spokes (1.1% of the portfolio), Julian and Felix Baker (1.0% of the portfolio), David Einhorn (0.1% of the portfolio).

Superinvestors holding IMVT

3 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:IMVT vs CAI (Immunovant, Inc. vs Caris Life Sciences)IMVT vs AMRX (Immunovant, Inc. vs Amneal Pharmaceuticals)IMVT vs BLCO (Immunovant, Inc. vs Bausch + Lomb)IMVT vs AXSM (Immunovant, Inc. vs Axsome Therapeutics)IMVT vs CHE (Immunovant, Inc. vs Chemed)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Immunovant, Inc. (IMVT): questions and answers

What is Immunovant, Inc.'s market cap?

Immunovant, Inc. is valued at $6.84B at a share price of $33.04.

Is IMVT above its 200-week moving average?

Yes. IMVT is 26.1% above its 200-week average of $26.21. Long-term investors watch that line because strong companies rarely trade below it for long.

Does IMVT pay a dividend?

Immunovant, Inc. does not currently pay a regular dividend.

Which famous investors own IMVT?

In their latest quarterly filings, Andrew Spokes (1.1% of the portfolio), Julian and Felix Baker (1.0% of the portfolio), David Einhorn (0.1% of the portfolio) hold IMVT. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

When does Immunovant, Inc. report earnings next?

Immunovant, Inc.'s next earnings report is expected on February 5, 2027. The date comes from the market data feed and companies do move it.

Cite this page

Funkfolio, “Immunovant, Inc. (IMVT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/IMVT

Underlying data: Yahoo Finance; company filings with the SEC.